What can we learn about dense low density lipoprotein and lipoprotein particles from clinical trials?
The small LDL pattern B trait, and triglyceride rich lipoproteins, have now been established as major coronary heart disease risk factors and have been associated with its severity. The presence of these disorders identifies a patient subgroup which is at substantial coronary artery disease risk but also exhibits the best arteriographic response to treatment. Most lipid-lowering treatments have a differential effect in LDL subclass pattern A patients compared with those with pattern B that helps explain the differential arteriographic response seen in clinical trials.
Superko
H R
HR
Berkeley Heart Lab, Cholesterol, Genetics and Heart Disease Institute, San Mateo, CA 94402, USA.
D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood* / Q000145:classification; D016896:Treatment Outcome
D008077:Lipoproteins, LDL